Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

EmbraceRX vs Telos Rx

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #453
EmbraceRX

EmbraceRX (Embrace Rx) is a clinician-guided telehealth platform offering pharmacy-compounded medications prescribed online, partnered with the Samaritan MD physician network.

Marked down on: Pricing not shown upfront — revealed only at checkout after a dose selection

vs
Dispatch #19Desk pick
Telos Rx

The broadest published catalog in the ranking — compounded GLP-1s plus oral and microdosed tirzepatide, PT-141, intranasal NAD+, and recovery peptides — all compounded and not FDA-approved.

$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks) sema · $139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide) tirz

Marked down on: Everything is compounded and not FDA-approved — including all peptides and the NAD+ spray

Telos Rx takes this head-to-head with the higher Desk Score, 85/100 (B) against 47/100 (C) for EmbraceRX. EmbraceRX still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

EmbraceRX

47/100

C

Overall

Telos Rx

85/100

B

Price transparency

20
74

State access

24
62

Molecule range

62
98

Onboarding speed

70
84

Support responsiveness

69
76

Licensing & trust

71
88

The spec sheet

FieldEmbraceRXTelos Rx
SemaglutideNot listed on EmbraceRX's site (checked June 23, 2026)$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks)
TirzepatideNot listed on EmbraceRX's site (checked June 23, 2026)$139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide)
CoverageNot listed on EmbraceRX's site (checked June 23, 2026)Not listed on Telos Rx's site
Brand-nameCompounded onlyCompounded only
Oral optionYesYes
Best forShoppers wanting compounded GLP-1 plus a deep peptide and longevity menu, prescribed online.Patients who want GLP-1 care alongside peptides, NAD+, and sexual-health options on one certified platform, with a needle-free oral or microdosed route.
Desk Score47/100C85/100B

The verdict

Desk pick — Telos Rx

Telos Rx takes this head-to-head with the higher Desk Score, 85/100 (B) against 47/100 (C) for EmbraceRX. EmbraceRX still holds its ground where its strengths line up with yours.

Choose EmbraceRX if…

Shoppers wanting compounded GLP-1 plus a deep peptide and longevity menu, prescribed online.

Choose Telos Rx if…

Patients who want GLP-1 care alongside peptides, NAD+, and sexual-health options on one certified platform, with a needle-free oral or microdosed route.

$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks) sema · $139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide) tirz

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: EmbraceRX · Telos Rx.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.